Co-immunoprecipitation (Co-IP) analyses demonstrated that treatment with INCB reduced binding of LSD1 with CoREST in the AML OCI-AML5, THP1, and in sAML SET-2 cells (Fig. 3A–C)25. This evidence concerns the gene SETD2 and acute myeloid leukemia.